MedTrace Logo

Parvovirus B19 Infection in Hereditary Hemolytic Anemias Patients

NCT04822090 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 244

Last updated 2021-03-30

No results posted yet for this study

Summary

Although many studies investigated the prevalence and manifestations of HPV-B19 infection in patients with sickle cell anemia (SCA), thalassemia, and hereditary spherocytosis (HS) separately, there is limited information about the extent to which HPV-B19 infection leads to severe complications and chronic infection.

Conditions

  • Parvovirus B19 Infection

Interventions

OTHER

Supportive treatment with or without red cell transfusion/intravenous immune globulin (IVIG)

red cell transfusion; plasma exchange; renal replacement therapy; intravenous immunoglobulin. plasma exchange

Sponsors & Collaborators

  • Assiut University

    collaborator OTHER

  • Sohag University

    lead OTHER

Principal Investigators

  • Mahmoud Yousef, MD, PhD · , Faculty of Medicine, Sohag University

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-10
Primary Completion
2021-02-10
Completion
2024-02-10

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04822090 on ClinicalTrials.gov